Immune sensing of a microbe occurs via multiple receptors. How signals from different receptors are coordinated to yield a specific immune response is poorly understood. We show that two pathogen recognition receptors, Toll-like receptor 2 (TLR2) and dectin-1, recognizing the same microbial stimulus, stimulate distinct innate and adaptive responses. TLR2 signaling induced splenic dendritic cells (DCs) to express the retinoic acid metabolizing enzyme retinaldehyde dehydrogenase type 2 and interleukin-10 (IL-10) and to metabolize vitamin A and stimulate Foxp3 + T regulatory cells (T reg cells). Retinoic acid acted on DCs to induce suppressor of cytokine signaling-3 expression, which suppressed activation of p38 mitogen-activated protein kinase and proinflammatory cytokines. Consistent with this finding, TLR2 signaling induced T reg cells and suppressed IL-23 and T helper type 17 (T H 17) and T H 1-mediated autoimmune responses in vivo. In contrast, dectin-1 signaling mostly induced IL-23 and proinflammatory cytokines and augmented T H 17 and T H 1-mediated autoimmune responses in vivo. These data define a new mechanism for the systemic induction of retinoic acid and immune suppression against autoimmunity.
It is now well established that a delicate balance between inflammatory versus regulatory responses underlies disease progression in many autoimmune disorders. DCs have emerged as central players in initiating and regulating adaptive immune responses [1] [2] [3] [4] [5] . Emerging evidence suggests that DCs are also vital in suppressing immune responses through the generation of anergic or T reg cells 6 . However, the mechanisms by which DCs can be programmed to induce T reg cells are poorly understood. DCs express several TLRs and the C-type lectins, which are crucial in sensing and initiating immune response against pathogens [7] [8] [9] . Engagement of such receptors programs gene expression that orchestrates DC maturation and activation 2, 7, 8 . The types of cytokines secreted by the DCs can regulate the differentiation of CD4 + T cells into T H 1, T H 2, T H 17 or T reg responses. For example, stimuli that induce IL-12 (p70) promote interferon-g (IFN-g)-producing T H 1 cells, stimuli that induce IL-10 favor T H 2 or T reg responses and stimuli that induce transforming growth factor-b (TGF-b), IL-6 and IL-23 promote T H 17 differentiation.
Zymosan, a yeast cell wall derivative, is a complex microbial stimulus that is recognized by many innate immune receptors, including TLR2 and dectin-1, a C-type lectin receptor for b-glucans [10] [11] [12] [13] [14] [15] . How signaling via both TLR2 and dectin-1 is integrated and influences adaptive immunity is poorly understood. Collaboration between TLR2 and dectin-1 results in the induction of proinflammatory cytokines in macrophages and DCs 14 , as well as robust IL-10 production in DCs [16] [17] [18] . Consistent with this, our previous work shows that zymosan conditions splenic DCs to secrete IL-10 and induce tolerogenic T cell responses 18 . Furthermore, zymosan is also known to induce splenic macrophages to secrete TGF-b 18 , a cytokine crucial for the generation of T reg cells, as well as T H 17 cells 11, [19] [20] [21] . In contrast, other studies have shown that dectin-1-mediated signaling in DCs induces T H 17 cells and IFN-g producing T H 1 cells 22, 23 .
Here we show that TLR2 and dectin-1 mediate divergent programs of DC activation, resulting in distinct adaptive responses to zymosan. Thus, zymosan induces retinaldehyde dehydrogenase type 2 (Raldh2) expression in DCs via a mechanism dependent largely on TLR2mediated activation of extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase (MAPK). Raldh2 converts vitamin A-derived retinal to retinoic acid, which acts in an autocrine manner to induce the expression of suppressor of cytokine signaling-3 (Socs3) and suppress activation of p38 MAPK and proinflammatory cytokines. Consistent with this, TLR2 signaling is crucial for zymosanmediated induction of T reg cells and suppression of T H 1 and T H 17 responses mediated autoimmunity in vivo; in the absence of TLR2 signaling, dectin-1-mediated signaling alone induced potent T H 1 and T H 17 responses and exacerbated autoimmunity.
RESULTS

Mechanism of induction of vitamin A-metabolizing enzymes
Zymosan is known to induce both proinflammatory [10] [11] [12] [13] [14] and antiinflammatory cytokines in DCs and macrophages [16] [17] [18] . Our previous study demonstrated that zymosan stimulates regulatory DCs and macrophages, which produce IL-10 and TGF-b, respectively 18 . One key variable in the different studies is the source and type of DCs. Therefore, it was necessary to determine whether zymosan stimulated similar cytokine profiles in both in vitro-generated bone marrowderived DCs (BMDCs), as well as in splenic DCs. In agreement with previously published reports 23, 24 , zymosan induced production of the proinflammatory cytokines IL-23, IL-6, IL-12 and TNF-a as well as IL-10 from BMDCs ( Supplementary Fig. 1 online) . In contrast, zymosan induced robust IL-10 production and little IL-23, IL-6, IL-12 and TNF-a production in splenic DCs in vitro ( Supplementary Fig. 2 online) and in vivo ( Supplementary Fig. 3a ,b online). Thus, zymosan induces distinct cytokine profiles depending on the type of DC.
To obtain insights into how zymosan activates splenic DCs, we performed a microarray analysis. Zymosan induced robust expression of the anti-inflammatory gene Il10 and much lower expression of pro-inflammatory genes such Il6, Tnfa, Il12a and Il12b, relative to lipopolysaccharide (LPS), a potent immune modulator (data not shown). Zymosan also induced expression of genes involved in the biosynthesis of retinoic acid such as Adh1 (encoding alcohol dehydrogenase 1) and Aldh1a2 (encoding Raldh2) (data not shown). This was unexpected, as splenic DCs, unlike intestinal DCs [25] [26] [27] [28] [29] [30] , are not thought to express these enzymes. Consistent with the microarray data, RT-PCR analysis showed that splenic DCs constitutively express the retinoic acid-metabolizing enzymes Adh class I (Adh1), Adh class III (Adh5), and low levels of Raldh1 (data not shown); upon zymosan treatment their expressions levels were further increased (data not shown). Notably, zymosan stimulated an 80-fold increase in the expression of Raldh2 mRNA (Fig. 1a) . In contrast, BMDCs stimulated with zymosan showed a modest increase in Raldh2 mRNA expression compared to the splenic DCs stimulated with zymosan (Supplementary Fig. 4 online) .
We next examined whether other TLR ligands could induce Raldh2 in DCs. Treatment with neither LPS (TLR4 ligand) nor CpG (TLR9 ligand) induced Raldh2 (Fig. 1b) . However, other ligands specific for TLR2 and TLR6, such as Pam-2-cys and follistatin-like 1 ligand induced substantial expression of Raldh2 (Fig. 1b) . Injection of zymosan into mice induced robust expression of Raldh2 messenger RNA in DCs (Fig. 1c) . The expression of Raldh2 protein in splenic DCs in vivo was confirmed by western blot analysis and immunohistochemical analysis ( Fig. 1d,e ). These data indicate that Raldh2 is robustly induced in splenic DCs upon stimulation with zymosan or other TLR2 or TLR6 ligands. Because zymosan signals through both TLR2 and dectin-1 (refs. [10] [11] [12] 14, 16, 18) , we determined whether induction of Raldh2 is dependent on both TLR2 and dectin-1. DCs from Tlr2 À/À mice expressed lower levels of Raldh2 mRNA compared to wild-type DCs upon zymosan stimulation ( Fig. 1f ). DCs from Tlr2 À/À mice showed a significant reduction in Raldh2 expression upon zymosan injection in vivo (Fig. 1f ). Treatment with curdlan, a b-glucan ligand that is thought to be a specific ligand for dectin-1 (ref. 16 ), induced Raldh2, albeit to a much lower level (12-fold, Fig. 1b ) than zymosan. However, DCs from dectin-1-deficient mice showed only a very modest reduction in Raldh2 mRNA levels compared to the wild-type DCs upon zymosan stimulation ( Fig. 1g ), suggesting that the effects of curdlan may have been mediated in part by contaminants that triggered TLR2; thus, dectin-1 probably does not have a major role in inducing Raldh2.
We next investigated the downstream signaling pathways through which TLR2 induces Raldh2 expression. TLR2 stimulates rapid induction of ERK, which mediates IL-10 production by DCs 16, 18, 23 . Induction of Raldh2 mRNA expression was largely abrogated by inhibitors against ERK ( Fig. 1h) . Additionally, DCs from Erk1 À/À mice had substantially reduced Raldh2 expression upon zymosan stimulation (data not shown). Furthermore, induction of Raldh2 was also inhibited substantially by a spleen tyrosine kinase (syk) inhibitor (data not shown). Thus, Raldh2 induction by zymosan is syk dependent but largely dectin-1 independent, suggesting that an alternative syk-dependent receptor is involved. In summary, therefore, zymosan induces Raldh2 expression in DCs via TLR2-mediated activation of ERK, probably acting in concert with syk-dependent signaling via another receptor.
Next, we determined whether production of Raldh2 and IL-10 in DCs were interdependent. Notably, induction of Il10 mRNA preceded that of Raldh2, raising the possibility that IL-10 may promote Raldh2 induction ( Supplementary Fig. 5a online). However, induction of Raldh2 was unaffected in DCs from IL-10-deficient mice (Supplementary Fig. 5b ). Conversely, blocking retinoic acid synthesis or retinoic acid signaling with antagonists to the retinoic acid receptor (RAR) had no effect on IL-10 production upon zymosan treatment ( Supplementary Fig. 5c ). Therefore, induction of IL-10 and Raldh2 do not seem to be interdependent.
Finally, we explored whether the mechanisms of Raldh2 induction observed with zymosan would also operate in response to a live yeast infection. Thus, we investigated whether the live pathogenic fungus Candida albicans triggered Raldh2 in splenic DCs. Stimulation of splenic DCs with live C. albicans induced Raldh2 mRNA and protein in wild-type DCs (Fig. 1i ), but this induction was significantly reduced in Tlr2 À/À DCs. Collectively, these results suggest a major role for TLR2-mediated ERK activation in the induction of Raldh2 in splenic DCs upon stimulation with zymosan or live yeast.
Retinoic acid and IL-10 act synergistically to induce T reg cells Next, we determined the roles of retinoic acid and IL-10 in the induction of T reg cells. In the presence of TGF-b, retinoic acid can promote the conversion of naive T cells to T reg cells expressing forkhead box P3 (Foxp3) [25] [26] [27] 29, 30 . Because zymosan induces enzymes involved in retinoic acid synthesis, we determined whether these DCs can metabolize vitamin A (retinol) to retinoic acid and induce T reg cells. Splenic DCs were stimulated with zymosan, or LPS or curdlan for 10 h and then washed and pulsed with a major histocompatibility complex I-A b -restricted ovalbumin peptide OVA 323-339 (OVA) and cultured with or without TGF-b, with naive OT-II CD4 + T cells, which express a transgenic T cell receptor specific for the OVA peptide 18 . After 4 d, OT-II T cells were restimulated with antibodies against CD3 and CD28. Zymosan-treated DCs in the absence of TGF-b induced mostly IL-10-producing T regulatory type 1 (T R 1) cells, whereas in the presence of TGF-b they induced both T reg cells and T R 1 cells ( Fig. 2a ). Zymosan-stimulated DCs did not induce marked T H 1 or T H 17 cell responses ( Fig. 2a) . In contrast, LPS-stimulated DCs induced marked T H 1 responses, and curdlan-stimulated DCs induced both T H 1 cells and T H-17 cells ( Fig. 2a) . Notably, in contrast to splenic DCs, zymosan-treated BMDCs induced T H 17 cells ( Supplementary  Fig. 6 online).
The proportion of T reg cells stimulated by zymosan-treated DCs was increased in the presence of retinol ( Fig. 2b) . To determine whether this effect is mediated through retinoic acid synthesis, we stimulated DCs with zymosan in the presence or absence of the Raldh inhibitor disulphiram, which inhibits retinoic acid synthesis by blocking its conversion from retinal [25] [26] [27] [28] [29] [30] . After 10 h, we washed the DCs were and cultured them with naive T cells in the presence of retinol and OVA. Inhibition of de novo retinoic acid synthesis in DCs suppressed zymosan-mediated induction of T reg cells (Fig. 2b) . Disulphiram also decreased the frequency of T reg cells that were induced in the absence of zymosan (data not shown). This may reflect expression of small amounts of Raldh1 in splenic DCs in response to signals from activated CD4 + T cells. This basal level of Raldh1 may have a role in converting prestored retinol to retinal in splenic DCs. Nevertheless, taken together, these results suggest zymosan induces splenic DCs to express retinoic acid-synthesizing proteins and stimulate T reg cells.
Of note, zymosan-treated DCs from Tlr2 À/À mice induced a significantly lower frequency of T reg cells compared to wild-type DCs (Fig. 2c ). Furthermore, zymosan-stimulated DCs treated with an ERK inhibitor were compromised in their ability to induce T reg cells (Fig. 2d) . However, addition of exogenous retinoic acid to the culture restored their ability to induce T reg cells (Fig. 2c) . These results are consistent with the effects of TLR2-mediated ERK signaling in inducing Raldh2 in DCs (Fig. 1f-h) . Thus, zymosan activates DCs via TLR2 to stimulate retinol-metabolizing enzymes, which induce T reg cells.
In addition to the effects of retinoic acid on the induction of T reg cells, IL-10 was also observed to have a role in experiments with a neutralizing antibody against IL-10 and its receptor ( Supplementary  Fig. 7a online) and DCs from Il10 À/À mice ( Supplementary Fig. 7b ). However, addition of retinol to these cultures markedly increased the proportion of T reg cells ( Supplementary Fig. 7b ). Consistent with these results, blocking IL-10 or retinoic acid-mediated signaling in DCs converts them from regulatory DCs to stimulatory DCs that induce enhanced T H 1 and T H 17 responses ( Supplementary Fig. 8a,b online). These results demonstrate that IL-10-deficient DCs can metabolize vitamin A as efficiently as wild-type DCs and that synthesis of IL-10 and retinoic acid are interdependent. Inhibition of retinoic acid or IL-10 alone results in a pronounced diminution of T reg cells, suggesting that IL-10 and retinoic acid act synergistically to induce T reg cells.
Autocrine effects of retinoic acid and IL-10 on DCs IL-10 exerts autocrine effects on DCs to suppress zymosan-induced proinflammatory cytokines 18 . Given the synergistic effects of retinoic acid and IL-10 in stimulating T reg cells, we hypothesized that retinoic acid might exert a similar effect on DCs. Thus, we determined the expression of the retinoic acid nuclear receptors RAR-a, RAR-b and RAR-g. We observed that all three receptors were expressed on DCs (Fig. 3a) . We stimulated DCs with zymosan in the presence or absence of retinol and determined the induction proinflammatory cytokines. Although zymosan-treated DCs produced little IL-6, IL-12 and TNF-a, addition of retinol further reduced the expression of these cytokines (Fig. 3b) . To determine whether this effect was dependent on RARs, we stimulated DCs with zymosan in the presence of retinol plus the RAR antagonist LE135/540. Addition of LE135/540 significantly increased the production of proinflammatory cytokines compared to addition of retinol alone (Fig. 3b) . Furthermore, DCs with IL-10 neutralized with an antibody (Fig. 3b) or DCs from Il10 À/À mice (Fig. 3c ) produced increased amounts of proinflammatory cytokines in response to zymosan; however, the addition of retinol or retinoic acid receptor antagonists produced the same effects observed with wild-type DCs (Fig. 3b,c) . These results indicate that retinoic acid produced by zymosan-treated DCs can act in an autocrine manner to suppress the production of proinflammatory cytokines.
In exploring the mechanisms by which retinoic acid suppresses the production of proinflammatory cytokines in zymosan-treated DCs, we observed an increase in the expression of Socs3 in zymosan-treated DCs relative to the untreated DCs in our microarray analysis (data not shown). This was confirmed by RT-PCR ( Fig. 3d) . Addition of retinol to the culture further increased Socs3 expression to approximately 20-fold above the control value; in contrast, addition of the RAR antagonist significantly lowered Socs3 mRNA expression ( Fig. 3d) . Thus, Socs3 is inducible upon zymosan stimulation and is partly dependent on RAR-mediated signaling. Consistent with this, knockdown of Raldh2 in DCs by small interfering RNA (siRNA) markedly reduced the induction of Socs3 in response to zymosan (Supplementary Fig. 9 online) . Furthermore, treatment with IL-10 also enhanced the induction of Socs3 expression by zymosan ( Fig. 3e) . DCs from Il10 À/À mice stimulated with zymosan showed a significant reduction in Socs3 expression, relative to wild-type DCs (Fig. 3d,e ), but this defect could be corrected by the addition of exogenous IL-10 or retinol to the culture (Fig. 3e) . Consistent with these in vitro observations, zymosan induced a significant (P o 0.001) increase in Socs3 expression in DCs within 3 h in vivo (Fig. 3f) . Furthermore, treatment of mice with disulphiram or LE135/540 reduced the level of Socs3 expression in vivo upon zymosan injection (Fig. 3g ). Induction of Socs3 was dependent on TLR2, as zymosan induced much lower levels of Socs3 in Tlr2 À/À mice relative to wild-type mice (Fig. 3h) .
Next, we determined the effect of retinoic acid on the activation of ERK and p38 MAPK. Blocking RAR-mediated signaling with LE135/540 led to a sustained activation of p38 but had no effect on ERK activation ( Supplementary Fig. 10a,c online) . Furthermore, IL-10 deficiency also resulted in a marked effect on the sustained expression of p38 MAPK in DCs ( Supplementary Fig. 10d ). This suggests that, similar to IL-10 signaling, retinoic acid signaling attenuates activation of p38 MAPK. To further address the role of Socs3 in zymosan-mediated suppression of proinflammatory cytokines, we knocked down Socs3 in DCs with siRNA ( Supplementary  Fig. 11 online) . DCs transfected with siRNA against Socs3 produced markedly higher levels of proinflammatory cytokines upon zymosan treatment compared to DCs transfected with control siRNA (Supplementary Fig. 11 ). Collectively, these results show that retinoic acidmeditated autocrine signaling is crucial for the induction of Socs3 and for regulating the activity of p38 MAPK and proinflammatory cytokines in zymosan-stimulated DCs.
TLR2 suppression of IL-23 and T H 17-mediated autoimmunity
To determine whether zymosan induces T reg cells in vivo, we adoptively transferred naive OT-II cells into wild-type, Tlr2 À/À or Il10 À/À mice and then immunized the mice with OVA alone or OVA mixed with either zymosan, or curdlan or LPS. After 4 d, we analyzed the proliferation and cytokine production of splenic OT-II T cells restimulated in vitro. Injection of zymosan and OVA resulted in a weak clonal expansion of antigen-specific T cells relative to injection of OVA and LPS or OVA and curdlan (data not shown). Consistent with this, stimulation with OVA and zymosan resulted in a robust induction of antigen-specific T reg cells and IL-10-producing T R 1 cells compared to stimulation with OVA and PBS or LPS or curdlan (Fig. 4a) .
Intracellular cytokine staining revealed robust induction of T H 1 responses in mice injected with LPS and induction of both T H 1 and T H 17 responses
in mice injected with curdlan ( Fig. 4a) . In contrast, mice injected with zymosan showed relatively weak T H 1 and T H 17 responses (Fig. 4a) . In Tlr2 À/À and Il10 À/À mice, induction of T reg cells was markedly reduced relative to wild-type mice (Fig. 4b) . Furthermore, in the knockout mice, zymosan induced enhanced T H 1 and T H 17 responses and induced a lower number of IL-10-producing cells (Fig. 4c) . These data suggest that TLR2-mediated signaling is crucial for the induction of both T reg cells and IL-10 + T R 1 cells. We next determined the therapeutic potential of zymosanstimulated T reg cells on autoimmune disease with a mouse model of experimental autoimmune encephalomyelitis (EAE). First, we immunized mice subcutaneously with myelin oligodendrocyte glycoprotein peptide (MOG ; defined here as MOG) emulsified in complete Freund's adjuvant (CFA) or with MOG and zymosan on days 0 and 7. As previously described 24 , mice treated with MOG and CFA showed onset of neurological impairment starting at around day 14 (Fig. 5a) . In contrast, MOG and zymosan treatment induced a relatively attenuated and transient disease course (Fig. 5a) . In Tlr2 À/À mice, injection of MOG and zymosan resulted in as severe a disease as observed in the positive control, suggesting a regulatory role for TLR2 in autoimmune disease (Fig. 5a) . We next determined whether zymosan is capable of actively suppressing disease. Thus, we immunized mice with MOG and CFA and simultaneously injected zymosan or curdlan. Control mice received PBS or curdlan and showed disease symptoms starting around day 14 after immunization (Fig. 5b) . In contrast, mice treated with zymosan developed significantly (P o 0.001) lower clinical scores compared to the PBS-or curdlan-treated mice (Fig. 5b) . Consistent with a regulatory role for TLR2 in autoimmune disease, zymosan treatment induced enhanced disease progression in Tlr2 À/À mice relative to wild-type mice (Fig. 5b) .
We then determined the phenotype of CD4 + T cells that had infiltrated the central nervous system at day 18 after immunization. We observed that zymosan treatment resulted in enhanced induction of T reg cells and T R 1 cells relative to treatment with PBS or curdlan (Fig. 5c) . In contrast, control or curdlan-treated mice showed a significant increase in the number of T H 1 and T H 17 cells compared to the zymosan-treated mice (Fig. 5c ). In Tlr2 À/À mice, there was a decreased frequency of T reg cells and T R 1 cells and greatly enhanced T H 1 and T H 17 responses (Fig. 5c) . Thus, TLR2-mediated signaling is essential for the induction of T reg cells and T R 
cells and suppresses T H and T H 17 responses.
IL-23 plays a pivotal part in the expansion of T H 17 cells and the pathogenesis of EAE. We thus evaluated the Il23a mRNA expression in DCs isolated ex vivo from wild-type versus Tlr2 À/À mice (Fig. 5d) . We also measured the serum cytokine concentrations of IL-23 in wild-type and Tlr2 À/À mice (Fig. 5e ) upon zymosan injection. Zymosan induced much higher expression of IL-23 in Tlr2 À/À mice relative to wild-type mice (Fig. 5d,e) . Similarly, DCs isolated from Tlr2 À/À mice produced significantly more IL-23 compared to wild-type DCs (Fig. 5f) . Collectively, these results suggest that TLR2-mediated signaling suppresses IL-23 production in DCs (Fig. 6) .
Finally, we investigated the relative roles of IL-10 and retinoic acid in zymosan-mediated suppression of EAE in Il10 À/À mice and Raldh inhibitor. Injection of disulphiram resulted in a significant (P o 0.01) but transient enhancement in the acceleration of the disease (Supplementary Fig. 12a online) . Furthermore, Il10 À/À mice were also more susceptible to EAE compared to the wild-type mice ( Supplementary  Fig. 12b ). Even in Il10 À/À mice, injection of disulphiram resulted in a marked enhancement in the disease severity ( Supplementary  Fig. 12b) . Similarly, wild-type mice injected with a Raldh inhibitor, encapsulated in microparticles, that specifically targets to antigenpresenting cells in vivo 31, 32 , showed worsened EAE upon zymosan treatment compared to the mice injected with empty particles ( Supplementary Fig. 12c ). These results collectively suggest that both retinoic acid and IL-10 contribute to the suppressive effect of zymosan (Fig. 6) .
DISCUSSION
Although recent studies have highlighted a major role for retinoic acid in the induction of T reg cells in the intestine 26, 27, 33, 34 , its role in systemic immune responses is poorly understood. The present data demonstrate that Raldh2 can be induced in splenic DCs via TLR2dependent ERK signaling, which programs DCs to induce T reg cells. Dectin-1 signaling seems largely irrelevant, although the dependence of Raldh2 induction on syk suggests that other syk-dependent receptors 14 may act in concert with TLR2 to induce Raldh2. Retinoic acid acts directly on T cells [25] [26] [27] [28] [29] [30] , but there is emerging evidence that retinoic acid can act also on DCs [35] [36] [37] [38] . Retinoids signal via two groups of nuclear receptors, the RAR receptors (RAR-a, RAR-b and RAR-g) and the retinoid X receptors (RXR-a, RXR-b and RXR-g) 39 . Our data show that DCs express RAR-a, RAR-b, RAR-g and RXR-a and that signaling via RARs is crucial for enhanced Raldh2 expression. This is consistent with reports in other cell types that retinoic acid regulates its own synthesis through RAR-mediated signaling and RALDH expression [40] [41] [42] [43] [44] . Furthermore, Raldh2 suppresses proinflammatory cytokines in DCs via induction of Socs3, a well known regulatory of proinflammatory responses [45] [46] [47] .
There are also conflicting reports on the effects of zymosan on innate and adaptive responses. Zymosan induces proinflammatory responses from macrophages and DCs [10] [11] [12] [13] [14] 16, 17 but also induces robust IL-10 production from DCs [16] [17] [18] . Our work shows that certain TLR2 ligands bias T cell differentiation toward the T H 2 pathway 48, 49 and that zymosan in particular induces tolerogenic responses 18 , results that contrast with recent findings that zymosan induces T H 17 responses 23, 24, 50 . One key variable in these studies is the type of DCs used. Our data suggest that splenic DCs produce an abundance of IL-10, but little or no proinflammatory cytokines, whereas BMDCs produce robust proinflammatory cytokines. Furthermore, zymosan induces splenic DCs to stimulate a predominantly T reg response, whereas it induces BMDCs to stimulate a T H 17 response. Consistent with this, BMDCs expressed high amounts of dectin-1 compared to splenic DCs, whereas TLR2 expression was comparable between BMDCs and splenic DCs (data not shown). Another variable is the dose of zymosan. Another group of researchers showed that injection of 500 mg of zymosan induced T H 17 responses and EAE, but only transiently 24 . Here we observed that injection of 100 mg of zymosan resulted in an active suppression of disease progression and a marked reduction in the frequency of T H 1 and T H 17 cells and an enhancement in the frequency of T reg cells and T R 1 cells. When we injected 500 mg of zymosan, we could only see a mild and transient disease of similar severity and kinetics to that observed with the lower dose (data not shown). The reasons for the difference between our study and the other researchers' 24 are not clear, but they may lie with differences between the mouse colonies used.
Finally, it is now clear that the immune system senses microbes not with a single innate immune receptor, but with a combination of several receptors 51 . Combinatorial triggering of specific TLRs on DCs induces synergistic responses 51 , and cooperation between TLRs and non-TLRs is known 9 , but its impact on adaptive immunity is poorly 
METHODS
Mice. We obtained C57BL/6, OT-II and B6.PL mice from Jackson Laboratories. We also obtained Il10 À/À mice (B6.129P2-Il10 tm1Cgn/J ) from Jackson Laboratories. We maintained the mice in specific pathogen-free conditions in the Emory Vaccine Center vivarium. All animal protocols were reviewed and approved by the Institutional Animal Care and Use Committee of Emory University.
Purification of splenic dendritic cells. In brief, we cut spleens from mice into small fragments and then digested the fragments with collagenase type 4 (1 mg ml -1 ) in complete DMEM plus 2% FBS for 30 min at 37 1C. We washed the cells twice and enriched CD11c + DCs with the CD11c-specific microbeads from Miltenyi Biotech. The resulting purity of CD11c + DCs was approximately 95%.
Toll-like receptor stimulation of dendritic cells. We cultured CD11c + splenic DCs (1 Â 10 6 cells per ml) for 24 h with Escherichia coli LPS (5 mg ml -1 ), Pam-3-cys (100 ng ml -1 ), Pam-2-cys (100 ng ml -1 ), CpG dinucleotides (1 mg ml -1 ), zymosan (25 mg ml -1 , Sigma) or curdlan (25 mg ml -1 , Wako). We collected the supernatants and used ELISA (Becton Dickinson and eBiosciences) to measure cytokine concentrations. In some experiments, we added antibody to IL-10 and antibody to IL-10R (1 mg ml -1 ), disulphiram (100 nM, Sigma) or LE135/LE540 (1 mM, Wako) for the duration of the stimulation.
In vitro cultures of mouse dendritic cells and T cells. For in vitro stimulation, we stimulated purified splenic CD11c + DCs (1 Â 10 6 cells per ml) with LPS (5 mg ml -1 ), zymosan (25 mg ml -1 ) or curdlan (25 mg ml -1 ) for 10 h and then washed them with medium three times. In some experiments, we cultured DCs with disulphiram (100 nM), Erk inhibitor (100 nM) or LE135/LE540 (1 mM) for the duration of stimulation. We washed activated DCs (2 Â 10 4 ) and then cultured them together with naive CD4 + CD62L + OT-II T cells (1 Â 10 5 ) and OVA (2 mg ml -1 ) in 200 ml RPMI complete medium in 96-well roundbottomed plates. We analyzed supernatants after 90 h, and we collected cells and analyzed them directly or re-stimulated them after 90 h. In some experiments, we added 500 nM retinol (Sigma), 1ng ml -1 TGF-b (R&D Systems) or both to cultures. We added antibody to mouse IL-10 (JES5-16E3; Becton Dickinson), antibody to IL-10R (1B1.3a; Becton Dickinson), antibody to human TGF-b (MAB1835; R&D Systems) or rat IgG isotype control antibody (A95-1; Becton Dickinson) ¼ to cultures at a final concentration of 10 mg ml -1 . We added LE135/LE540 to some cultures at a concentration of 1 mM. For secondary re-stimulation, we collected cells after 90 h of primary culture, and then re-stimulated them for 6 h with plate-bound antibody to CD3 (10 mg ml -1 ; 145.2C11 from Becton Dickinson) and antibody to CD28 (2 mg ml -1 ; 37.51 from Becton Dickinson) in the presence of brefeldin A (Becton Dickinson) for intracellular cytokine detection, or we re-stimulated them with OVA (2 mg ml -1 ) for 48 h for analysis of proliferation and cytokine production in cell supernatants.
Statistical analyses. We conducted statistical analyses with GraphPad Prism software. We analyzed mean clinical scores with the Mann-Whitney nonparametric t test. We calculated the statistical significance of differences in the mean concencentrations ± s.d. of cytokines released by cells of various types with Student's t test (one-tailed).
